Acute Myeloid Leukemia Refractory Clinical Trials

28 clinical trials for Acute Myeloid Leukemia Refractory across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Master Framework For Relapse or Refractory Acute Myeloid Leukemia — RECRUITING
• Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) — RECRUITING · PHASE2
• A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia — RECRUITING · PHASE1
• A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS — RECRUITING · PHASE1
• Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Venetoclax to Augment Epigenetic Modification and Chemotherapy — RECRUITING · PHASE1
• PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML — RECRUITING · PHASE1
• Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS — RECRUITING · PHASE1
• AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies — RECRUITING · PHASE1
• Study of REM-422 in Patients With AML or Higher Risk MDS — RECRUITING · PHASE1
• Off-the-shelf CD123 CAR-NK for R/R AML — RECRUITING · PHASE1
• A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) — RECRUITING · PHASE1
• Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Lentivirally Redirected CD123 Autologous T Cells in AML — TERMINATED · PHASE1
• Natural Killer-cell Therapy for Acute Myeloid Leukemia — TERMINATED · PHASE1
• KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• CD123 Redirected T Cells for AML in Pediatric Subjects — TERMINATED · PHASE1
• An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia — NOT_YET_RECRUITING · PHASE1
• CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] — TERMINATED · PHASE1
• CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) — WITHDRAWN · PHASE2
• Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — OTHER · PHASE1
• A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML — TERMINATED · PHASE1
• Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia — OTHER · PHASE1
• Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) — OTHER · PHASE1

Refine this search